• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 10-Q filed by Innospec Inc.

    5/8/26 9:34:33 AM ET
    $IOSP
    Major Chemicals
    Industrials
    Get the next $IOSP alert in real time by email
    10-Q
    Q1false0001054905--12-31DEhttp://innospec.com/20260331#PresidentAndChiefExecutiveOfficerMember0001054905us-gaap:ComputerSoftwareIntangibleAssetMember2026-01-012026-03-310001054905srt:MaximumMemberiosp:EuropeanMetalRecyclingLimitedMember2026-01-012026-03-3100010549052026-03-310001054905us-gaap:RevolvingCreditFacilityMember2025-12-310001054905us-gaap:RetainedEarningsMember2024-12-310001054905iosp:OtherNetIncomeExpenseMemberus-gaap:NondesignatedMemberus-gaap:ForeignExchangeContractMember2025-01-012025-03-310001054905us-gaap:AccumulatedTranslationAdjustmentMember2026-01-012026-03-310001054905iosp:GermanPlanMembercountry:DE2026-01-012026-03-310001054905us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2026-03-310001054905iosp:GermanPlanMembercountry:DE2025-01-012025-03-3100010549052026-01-012026-03-310001054905srt:MaximumMember2026-01-012026-03-310001054905iosp:OtherPerformanceChemicalsMemberus-gaap:OperatingSegmentsMemberiosp:PerformanceChemicalsMember2026-01-012026-03-310001054905us-gaap:CarryingReportedAmountFairValueDisclosureMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2025-12-310001054905us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2025-01-012025-03-310001054905us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:EstimateOfFairValueFairValueDisclosureMember2025-12-310001054905us-gaap:AdditionalPaidInCapitalMember2025-01-012025-03-310001054905us-gaap:RetainedEarningsMember2025-03-310001054905iosp:PerformanceChemicalsMember2026-01-012026-03-310001054905us-gaap:OperatingSegmentsMemberiosp:OilfieldServicesMember2025-01-012025-03-310001054905us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2026-01-012026-03-310001054905us-gaap:OperatingSegmentsMemberiosp:FuelSpecialtiesMemberiosp:OtherFuelSpecialtiesMember2026-01-012026-03-310001054905us-gaap:AccumulatedOtherComprehensiveIncomeMember2026-03-310001054905us-gaap:OperatingSegmentsMemberiosp:PerformanceChemicalsMember2025-01-012025-03-310001054905iosp:EuropeanMetalRecyclingLimitedMember2025-12-3100010549052026-04-300001054905us-gaap:RevolvingCreditFacilityMember2026-03-310001054905us-gaap:RetainedEarningsMember2026-03-310001054905us-gaap:AccumulatedTranslationAdjustmentMember2024-12-310001054905us-gaap:OperatingSegmentsMemberiosp:PerformanceChemicalsMember2026-01-012026-03-310001054905us-gaap:TreasuryStockCommonMember2025-12-310001054905us-gaap:AdditionalPaidInCapitalMember2024-12-310001054905us-gaap:EmployeeStockOptionMember2026-01-012026-03-310001054905us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-12-310001054905us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-12-310001054905us-gaap:TreasuryStockCommonMember2026-03-310001054905iosp:RemediationMember2026-01-012026-03-310001054905us-gaap:OperatingSegmentsMemberiosp:FuelSpecialtiesMemberiosp:RefineryAndPerformanceMember2025-01-012025-03-310001054905iosp:StockEquivalentUnitsMember2025-01-012025-03-310001054905us-gaap:OperatingSegmentsMember2026-01-012026-03-310001054905us-gaap:NoncontrollingInterestMember2025-03-310001054905us-gaap:RevolvingCreditFacilityMember2026-01-012026-03-310001054905us-gaap:CarryingReportedAmountFairValueDisclosureMemberiosp:EmissionTradingSchemeCreditsMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2025-12-3100010549052025-01-012025-03-310001054905us-gaap:NoncontrollingInterestMember2024-12-310001054905us-gaap:OperatingSegmentsMemberiosp:HomeCareMemberiosp:PerformanceChemicalsMember2025-01-012025-03-310001054905us-gaap:AccumulatedOtherComprehensiveIncomeMember2026-01-012026-03-310001054905us-gaap:RetainedEarningsMember2025-01-012025-03-310001054905us-gaap:CorporateNonSegmentMember2026-01-012026-03-310001054905us-gaap:FairValueInputsLevel3Memberus-gaap:CarryingReportedAmountFairValueDisclosureMemberus-gaap:FairValueMeasurementsRecurringMember2026-03-310001054905us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2026-01-012026-03-310001054905us-gaap:OperatingSegmentsMemberiosp:HomeCareMemberiosp:PerformanceChemicalsMember2026-01-012026-03-3100010549052024-12-310001054905us-gaap:RetainedEarningsMember2025-12-310001054905us-gaap:OperatingSegmentsMemberiosp:FuelSpecialtiesMemberiosp:RefineryAndPerformanceMember2026-01-012026-03-310001054905us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2025-12-310001054905iosp:EuropeanMetalRecyclingLimitedMember2026-03-310001054905us-gaap:EmployeeStockOptionMember2025-01-012025-03-310001054905us-gaap:OperatingSegmentsMemberiosp:FuelSpecialtiesMemberiosp:OtherFuelSpecialtiesMember2025-01-012025-03-310001054905us-gaap:OperatingSegmentsMemberiosp:OilfieldServicesMember2026-01-012026-03-310001054905us-gaap:FairValueInputsLevel1Memberus-gaap:ForeignExchangeContractMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:EstimateOfFairValueFairValueDisclosureMember2025-12-310001054905us-gaap:CarryingReportedAmountFairValueDisclosureMemberus-gaap:FairValueInputsLevel1Memberus-gaap:ForeignExchangeContractMemberus-gaap:FairValueMeasurementsRecurringMember2025-12-310001054905us-gaap:CommonStockMember2024-12-310001054905us-gaap:FairValueInputsLevel1Memberus-gaap:ForeignExchangeContractMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:EstimateOfFairValueFairValueDisclosureMember2026-03-310001054905us-gaap:OperatingSegmentsMemberiosp:FuelSpecialtiesMember2025-01-012025-03-310001054905us-gaap:AccumulatedTranslationAdjustmentMember2025-01-012025-03-310001054905us-gaap:CommonStockMember2025-12-310001054905us-gaap:TreasuryStockCommonMember2024-12-310001054905us-gaap:AccumulatedTranslationAdjustmentMember2025-12-310001054905us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2024-12-3100010549052025-12-310001054905us-gaap:AdditionalPaidInCapitalMember2026-01-012026-03-310001054905srt:EuropeMember2025-12-310001054905us-gaap:RetainedEarningsMember2026-01-012026-03-310001054905iosp:EmissionTradingSchemeCreditsMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:EstimateOfFairValueFairValueDisclosureMember2026-03-310001054905us-gaap:NoncontrollingInterestMember2025-12-310001054905iosp:FuelSpecialtiesMember2026-01-012026-03-310001054905us-gaap:NoncontrollingInterestMember2026-03-310001054905us-gaap:AdditionalPaidInCapitalMember2026-03-310001054905srt:EuropeMember2026-03-310001054905iosp:EmissionTradingSchemeCreditsMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:EstimateOfFairValueFairValueDisclosureMember2025-12-310001054905us-gaap:TreasuryStockCommonMember2025-03-310001054905us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2025-03-310001054905iosp:OtherNetIncomeExpenseMemberus-gaap:NondesignatedMemberus-gaap:ForeignExchangeContractMember2026-01-012026-03-310001054905us-gaap:TreasuryStockCommonMember2026-01-012026-03-310001054905us-gaap:OperatingSegmentsMemberiosp:PersonalCareMemberiosp:PerformanceChemicalsMember2025-01-012025-03-310001054905iosp:QuimicaGeralSAMember2026-01-012026-03-310001054905iosp:OtherPerformanceChemicalsMemberus-gaap:OperatingSegmentsMemberiosp:PerformanceChemicalsMember2025-01-012025-03-3100010549052026-01-010001054905us-gaap:CarryingReportedAmountFairValueDisclosureMemberiosp:EmissionTradingSchemeCreditsMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2026-03-310001054905us-gaap:AdditionalPaidInCapitalMember2025-12-310001054905us-gaap:NoncontrollingInterestMember2025-01-012025-03-310001054905us-gaap:CommonStockMember2025-03-310001054905us-gaap:CommonStockMember2026-03-310001054905us-gaap:OperatingSegmentsMember2025-01-012025-03-310001054905us-gaap:AccumulatedTranslationAdjustmentMember2025-03-310001054905us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-01-012025-03-310001054905us-gaap:TreasuryStockCommonMember2025-01-012025-03-310001054905us-gaap:RevolvingCreditFacilityMember2025-01-012025-03-310001054905us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-03-310001054905us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:EstimateOfFairValueFairValueDisclosureMember2026-03-310001054905iosp:StockEquivalentUnitsMember2026-01-012026-03-310001054905us-gaap:CorporateNonSegmentMember2025-01-012025-03-310001054905us-gaap:CarryingReportedAmountFairValueDisclosureMemberus-gaap:FairValueInputsLevel1Memberus-gaap:ForeignExchangeContractMemberus-gaap:FairValueMeasurementsRecurringMember2026-03-310001054905srt:MaximumMemberiosp:EuropeanMetalRecyclingLimitedMember2025-01-012025-03-310001054905us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2025-01-012025-03-3100010549052025-03-310001054905us-gaap:AccumulatedTranslationAdjustmentMember2026-03-310001054905iosp:RemediationMember2025-01-012025-03-310001054905us-gaap:NoncontrollingInterestMember2026-01-012026-03-310001054905us-gaap:AdditionalPaidInCapitalMember2025-03-310001054905us-gaap:OperatingSegmentsMemberiosp:PersonalCareMemberiosp:PerformanceChemicalsMember2026-01-012026-03-310001054905us-gaap:OperatingSegmentsMemberiosp:FuelSpecialtiesMember2026-01-012026-03-31xbrli:pureiso4217:USDxbrli:sharesxbrli:sharesiosp:Segmentiso4217:USD

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

    FORM 10-Q

    ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

    For the quarterly period ended March 31, 2026

    or

    ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

    For the transition period from to

    Commission file number 1-13879

    INNOSPEC INC.

    (Exact name of registrant as specified in its charter)

     

     

    DELAWARE

     

    98-0181725

     

     

    (State or other jurisdiction of incorporation or organization)

     

    (I.R.S. Employer

    Identification No.)

     

     

     

     

     

     

     

    8310 South Valley Highway Suite 350

    Englewood

     

     

     

     

     

     

     

     

     

    Colorado

     

    80112

     

     

    (Address of principal executive offices)

     

    (Zip Code)

     

     

    Registrant’s telephone number, including area code: (303) 792 5554

     

    Securities registered pursuant to Section 12(b) of the Securities Exchange Act of 1934:

     

    Title of each class

     

    Trading

    Symbol(s)

     

    Name of each exchange

    on which registered

    Common stock, par value $0.01 per share

     

    IOSP

     

    NASDAQ

     

    Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

    Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such file. Yes ☒ No ☐

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer

    ☒

    Accelerated filer

    ☐

    Non-accelerated filer

    ☐

    Smaller reporting company

    ☐

    Emerging growth company

    ☐

     

     

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial standards provided pursuant to Section 13(a) of the Exchange Act. ☐

    Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

    Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date.

     

     

    Class

     

    Outstanding as of April 30, 2026

     

     

    Common Stock, par value $0.01

     

    24,631,047

     

     

     


     

    TABLE OF CONTENTS

     

     

     

    PART I

    FINANCIAL INFORMATION

    2

    Item 1

    Condensed Consolidated Financial Statements

    2

     

    Condensed Consolidated Statements of Income

    2

     

    Condensed Consolidated Statements of Comprehensive Income

    3

     

    Condensed Consolidated Balance Sheets

    4

     

    Condensed Consolidated Statements of Cash Flows

    5

     

    Condensed Consolidated Statements of Equity

    6

     

    Notes To The Unaudited Interim Condensed Consolidated Financial Statements

    7

    Item 2

    Management’s Discussion and Analysis of Financial Condition and Results of Operations for the Three months ended March 31, 2026 and 2025

    17

     

    Critical Accounting Estimates

    17

     

    Results of Operations

    17

     

    Liquidity and Financial Condition

    21

    Item 3

    Quantitative and Qualitative Disclosures about Market Risk

    23

    Item 4

    Controls and Procedures

    23

    PART II

    OTHER INFORMATION

    25

    Item 1

    Legal Proceedings

    25

    Item 1A

    Risk Factors

    25

    Item 2

    Unregistered Sales of Equity Securities and Use of Proceeds

    25

    Item 3

    Defaults Upon Senior Securities

    26

    Item 4

    Mine Safety Disclosures

    26

    Item 5

    Other Information

    26

    Item 6

    Exhibits

    27

     

    SIGNATURES

     

    28

     

     


     

    CAUTIONARY STATEMENT RELATIVE TO FORWARD-LOOKING STATEMENTS

    This Form 10-Q contains certain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts included or incorporated herein may constitute forward-looking statements. Such forward-looking statements include statements (covered by words like “expects,” “estimates,” “anticipates,” “may,” “could,” “believes,” “feels,” “plans,” “intends,” “outlook” or similar words or expressions, for example) which relate to earnings, growth potential, operating performance, events or developments that we expect or anticipate will or may occur in the future. Although forward-looking statements are believed by management to be reasonable when made, they are subject to certain risks, uncertainties and assumptions, and our actual performance or results may differ materially from these forward-looking statements. Additional information regarding risks, uncertainties and assumptions relating to Innospec and affecting our business operations and prospects are described in Innospec’s Annual Report on Form 10-K for the year ended December 31, 2025, and other reports filed with the U.S. Securities and Exchange Commission ("SEC"). You are urged to review our discussion of risks and uncertainties that could cause actual results to differ from forward-looking statements under the heading “Risk Factors” in such reports. Innospec undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

    1


     

    PART I FINANCIAL INFORMATION

    Item 1 Condensed Consolidated Financial Statements

    INNOSPEC INC. AND SUBSIDIARIES

    CONDENSED CONSOLIDATED STATEMENTS OF INCOME

    (Unaudited)

     

     

    Three Months Ended
    March 31,

     

    (in millions, except share and per share data)

     

    2026

     

     

    2025

     

    Net sales

     

    $

    453.2

     

     

    $

    440.8

     

    Cost of goods sold

     

     

    (329.7

    )

     

     

    (315.7

    )

    Gross profit

     

     

    123.5

     

     

     

    125.1

     

    Operating expenses:

     

     

     

     

     

     

    Selling, general and administrative

     

     

    (78.5

    )

     

     

    (69.3

    )

    Research and development

     

     

    (13.2

    )

     

     

    (12.7

    )

    Adjustment to fair value of contingent consideration

     

     

    4.7

     

     

     

    (0.7

    )

    Profit on disposal of property, plant and equipment

     

     

    —

     

     

     

    0.1

     

    Total operating expenses

     

     

    (87.0

    )

     

     

    (82.6

    )

    Operating income

     

     

    36.5

     

     

     

    42.5

     

    Other income/(expense), net

     

     

    2.6

     

     

     

    0.3

     

    Interest income, net

     

     

    0.8

     

     

     

    2.4

     

    Income before income tax expense

     

     

    39.9

     

     

     

    45.2

     

    Income tax expense

     

     

    (9.1

    )

     

     

    (11.6

    )

    Net income

     

     

    30.8

     

     

     

    33.6

     

    Less: Net income attributable to noncontrolling interests

     

     

    (0.4

    )

     

     

    (0.8

    )

    Net income attributable to Innospec

     

    $

    30.4

     

     

    $

    32.8

     

    Earnings per share:

     

     

     

     

     

     

    Basic

     

    $

    1.23

     

     

    $

    1.31

     

    Diluted

     

    $

    1.22

     

     

    $

    1.31

     

    Weighted average shares outstanding (in thousands):

     

     

     

     

     

     

    Basic

     

     

    24,776

     

     

     

    24,970

     

    Diluted

     

     

    24,844

     

     

     

    25,102

     

     

    The accompanying notes are an integral part of these unaudited interim condensed consolidated financial statements.

    2


     

    INNOSPEC INC. AND SUBSIDIARIES

    CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME

    (Unaudited)

     

     

    Three Months Ended
    March 31,

     

    (in millions)

     

    2026

     

     

    2025

     

    Net income attributable to Innospec

     

    $

    30.4

     

     

    $

    32.8

     

    Other comprehensive income/(loss):

     

     

     

     

     

     

       Changes in cumulative translation adjustment

     

     

    (5.0

    )

     

     

    18.4

     

    Other comprehensive income/(loss), before tax

     

     

    (5.0

    )

     

     

    18.4

     

    Tax related to cumulative translation adjustment

     

     

    (1.1

    )

     

     

    0.3

     

    Income tax income/(expense) related to other comprehensive income

     

     

    (1.1

    )

     

     

    0.3

     

    Total comprehensive income attributable to Innospec

     

    $

    24.3

     

     

    $

    51.5

     

     

     

    The accompanying notes are an integral part of these unaudited interim condensed consolidated financial statements.

    3


     

    INNOSPEC INC. AND SUBSIDIARIES

    CONDENSED CONSOLIDATED BALANCE SHEETS

    (Unaudited)

    (in millions, except share and per share data)

     

    March 31,
    2026

     

     

    December 31,
    2025

     

    Assets

     

     

     

     

     

     

    Current assets:

     

     

     

     

     

     

    Cash and cash equivalents

     

    $

    289.1

     

     

    $

    292.5

     

    Trade and other accounts receivable (less allowances of $14.2 million and $11.8 million respectively)

     

     

    354.2

     

     

     

    342.3

     

    Inventories (less allowances of $39.4 million and $40.4 million respectively):

     

     

     

     

     

     

    Finished goods

     

     

    225.6

     

     

     

    226.3

     

    Raw materials

     

     

    95.9

     

     

     

    103.0

     

    Total inventories

     

     

    321.5

     

     

     

    329.3

     

    Prepaid expenses

     

     

    16.9

     

     

     

    20.1

     

    Prepaid income taxes

     

     

    10.6

     

     

     

    13.1

     

    Other current assets

     

     

    6.8

     

     

     

    7.3

     

    Total current assets

     

     

    999.1

     

     

     

    1,004.6

     

    Net property, plant and equipment

     

     

    285.7

     

     

     

    286.1

     

    Operating lease right-of-use assets

     

     

    50.6

     

     

     

    52.7

     

    Goodwill

     

     

    399.1

     

     

     

    399.0

     

    Other intangible assets

     

     

    68.9

     

     

     

    67.7

     

    Deferred tax assets

     

     

    13.0

     

     

     

    13.6

     

    Other non-current assets

     

     

    3.4

     

     

     

    8.7

     

    Total assets

     

    $

    1,819.8

     

     

    $

    1,832.4

     

     

    Liabilities and Equity

     

     

     

     

     

     

    Current liabilities:

     

     

     

     

     

     

    Accounts payable

     

    $

    138.5

     

     

    $

    174.7

     

    Accrued liabilities

     

     

    169.3

     

     

     

    152.3

     

    Current portion of operating lease liabilities

     

     

    15.1

     

     

     

    15.9

     

    Current portion of plant closure provisions

     

     

    4.9

     

     

     

    4.9

     

    Current portion of acquisition-related contingent consideration

     

     

    2.7

     

     

     

    7.0

     

    Accrued income taxes

     

     

    4.3

     

     

     

    5.3

     

    Total current liabilities

     

     

    334.8

     

     

     

    360.1

     

    Operating lease liabilities, net of current portion

     

     

    35.5

     

     

     

    36.8

     

    Plant closure provisions, net of current portion

     

     

    60.8

     

     

     

    60.2

     

    Deferred tax liabilities

     

     

    17.9

     

     

     

    19.1

     

    Pension liabilities and post-employment benefits

     

     

    12.8

     

     

     

    13.2

     

    Acquisition-related contingent consideration

     

     

    1.3

     

     

     

    1.3

     

    Other non-current liabilities

     

     

    4.5

     

     

     

    8.8

     

    Total liabilities

     

     

    467.6

     

     

     

    499.5

     

    Equity:

     

     

     

     

     

     

    Common stock, $0.01 par value, authorized 40,000,000 shares, issued 29,554,500
       shares

     

     

    0.3

     

     

     

    0.3

     

    Additional paid-in capital

     

     

    377.3

     

     

     

    376.5

     

    Treasury stock (4,836,364 and 4,776,918 shares at cost, respectively)

     

     

    (121.4

    )

     

     

    (115.2

    )

    Retained earnings

     

     

    1,129.6

     

     

     

    1,099.2

     

    Accumulated other comprehensive loss

     

     

    (40.8

    )

     

     

    (34.7

    )

    Total Innospec stockholders’ equity

     

     

    1,345.0

     

     

     

    1,326.1

     

    Non-controlling interest

     

     

    7.2

     

     

     

    6.8

     

    Total equity

     

     

    1,352.2

     

     

     

    1,332.9

     

    Total liabilities and equity

     

    $

    1,819.8

     

     

    $

    1,832.4

     

     

    The accompanying notes are an integral part of these unaudited interim condensed consolidated financial statements.

    4


     

    INNOSPEC INC. AND SUBSIDIARIES

    CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

    (Unaudited)

     

     

    Three Months Ended
    March 31,

     

    (in millions)

     

    2026

     

     

    2025

     

    Cash Flows from Operating Activities

     

     

     

     

     

     

    Net income attributable to Innospec

     

    $

    30.4

     

     

    $

    32.8

     

    Adjustments to reconcile net income attributable to Innospec to net cash provided by operating activities:

     

     

     

     

     

     

    Depreciation and amortization

     

     

    9.9

     

     

     

    10.9

     

    Adjustment to fair value of contingent consideration

     

     

    (4.7

    )

     

     

    0.7

     

    Deferred taxes

     

     

    (0.7

    )

     

     

    (0.3

    )

    Profit on disposal of property, plant and equipment

     

     

    —

     

     

     

    (0.1

    )

    Movements on defined benefit pension plans

     

     

    (0.2

    )

     

     

    1.3

     

    Stock option compensation

     

     

    1.6

     

     

     

    1.9

     

    Changes in assets and liabilities, net of effects of acquired and divested companies:

     

     

     

     

     

     

    Trade and other accounts receivable

     

     

    (13.7

    )

     

     

    6.6

     

    Inventories

     

     

    5.9

     

     

     

    (6.6

    )

    Prepaid expenses

     

     

    3.2

     

     

     

    5.4

     

    Accounts payable and accrued liabilities

     

     

    (17.7

    )

     

     

    (27.0

    )

    Plant closure provisions

     

     

    1.5

     

     

     

    (0.4

    )

    Income taxes

     

     

    0.4

     

     

     

    4.3

     

    Other assets and liabilities

     

     

    1.7

     

     

     

    (1.2

    )

    Net cash provided by operating activities

     

     

    17.6

     

     

     

    28.3

     

    Cash Flows from Investing Activities

     

     

     

     

     

     

    Capital expenditures

     

     

    (8.9

    )

     

     

    (8.4

    )

    Internally developed software

     

     

    (5.1

    )

     

     

    (7.2

    )

    Proceeds on disposal of property, plant and equipment

     

     

    0.3

     

     

     

    0.1

     

    Net cash used in investing activities

     

     

    (13.7

    )

     

     

    (15.5

    )

    Cash Flows from Financing Activities

     

     

     

     

     

     

    Non-controlling interest

     

     

    0.4

     

     

     

    0.8

     

    Issue of treasury stock

     

     

    0.1

     

     

     

    0.2

     

    Repurchase of common stock

     

     

    (7.1

    )

     

     

    (4.8

    )

    Net cash used in financing activities

     

     

    (6.6

    )

     

     

    (3.8

    )

    Effect of foreign currency exchange rate changes on cash

     

     

    (0.7

    )

     

     

    1.6

     

    Net change in cash and cash equivalents

     

     

    (3.4

    )

     

     

    10.6

     

    Cash and cash equivalents at beginning of period

     

     

    292.5

     

     

     

    289.2

     

    Cash and cash equivalents at end of period

     

    $

    289.1

     

     

    $

    299.8

     

     

    The accompanying notes are an integral part of these unaudited interim condensed consolidated financial statements.

    5


     

    INNOSPEC INC. AND SUBSIDIARIES

    CONDENSED CONSOLIDATED STATEMENTS OF EQUITY

    (Unaudited)

     

    (in millions)

     

    Common
    Stock

     

     

    Additional
    Paid-In
    Capital

     

     

    Treasury
    Stock

     

     

    Retained
    Earnings

     

     

    Accumulated
    Other
    Comprehensive
    Loss

     

     

    Non-
    Controlling
    Interest

     

     

    Total
    Equity

     

    Balance at December 31, 2025

     

    $

    0.3

     

     

    $

    376.5

     

     

    $

    (115.2

    )

     

    $

    1,099.2

     

     

    $

    (34.7

    )

     

    $

    6.8

     

     

    $

    1,332.9

     

    Net income attributable to Innospec

     

     

     

     

     

     

     

     

     

     

     

    30.4

     

     

     

     

     

     

     

     

     

    30.4

     

    Changes in cumulative translation adjustment,
       net of tax

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    (6.1

    )

     

     

     

     

     

    (6.1

    )

    Share of net income

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    0.4

     

     

     

    0.4

     

    Treasury stock reissued

     

     

     

     

     

    (1.0

    )

     

     

    0.8

     

     

     

     

     

     

     

     

     

     

     

     

    (0.2

    )

    Treasury stock repurchased

     

     

     

     

     

     

     

     

    (7.0

    )

     

     

     

     

     

     

     

     

     

     

     

    (7.0

    )

    Stock option compensation

     

     

     

     

     

    1.8

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    1.8

     

    Balance at March 31, 2026

     

    $

    0.3

     

     

    $

    377.3

     

     

    $

    (121.4

    )

     

    $

    1,129.6

     

     

    $

    (40.8

    )

     

    $

    7.2

     

     

    $

    1,352.2

     

     

    (in millions)

     

    Common
    Stock

     

     

    Additional
    Paid-In
    Capital

     

     

    Treasury
    Stock

     

     

    Retained
    Earnings

     

     

    Accumulated
    Other
    Comprehensive
    Loss

     

     

    Non-
    Controlling
    Interest

     

     

    Total
    Equity

     

    Balance at December 31, 2024

     

    $

    0.3

     

     

    $

    369.9

     

     

    $

    (93.0

    )

     

    $

    1,025.0

     

     

    $

    (91.0

    )

     

    $

    4.9

     

     

    $

    1,216.1

     

    Net income attributable to Innospec

     

     

     

     

     

     

     

     

     

     

     

    32.8

     

     

     

     

     

     

     

     

     

    32.8

     

    Changes in cumulative translation adjustment, net of tax

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    18.7

     

     

     

     

     

     

    18.7

     

    Share of net income

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    0.8

     

     

     

    0.8

     

    Treasury stock reissued

     

     

     

     

     

    (1.1

    )

     

     

    1.3

     

     

     

     

     

     

     

     

     

     

     

     

    0.2

     

    Treasury stock repurchased

     

     

     

     

     

     

     

     

    (4.8

    )

     

     

     

     

     

     

     

     

     

     

     

    (4.8

    )

    Stock option compensation

     

     

     

     

     

    1.9

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    1.9

     

    Balance at March 31, 2025

     

    $

    0.3

     

     

    $

    370.7

     

     

    $

    (96.5

    )

     

    $

    1,057.8

     

     

    $

    (72.3

    )

     

    $

    5.7

     

     

    $

    1,265.7

     

     

    The accompanying notes are an integral part of these unaudited interim condensed consolidated financial statements.

     

     

    6


     

    INNOSPEC INC. AND SUBSIDIARIES

    NOTES TO THE UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

    NOTE 1 – BASIS OF PRESENTATION

    The accompanying unaudited interim condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X under the Securities Exchange Act of 1934. Accordingly, they do not include all the information and notes necessary for a comprehensive presentation of financial position, results of operations and cash flows.

    It is our opinion, however, that all adjustments (consisting of normal, recurring adjustments, unless otherwise disclosed) have been made which are necessary for a fair statement of the condensed consolidated financial statements. These condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025, filed on February 18, 2026 (the “2025 Form 10-K”).

    The results for the interim period covered by this report are not necessarily indicative of the results to be expected for the full year.

    When we use the terms “Innospec,” “the Corporation,” “the Company,” “Registrant,” “the Group,” “we,” “us” and “our,” we are referring to Innospec Inc. and its consolidated subsidiaries unless otherwise indicated or the context otherwise requires.

    NOTE 2 – SEGMENT REPORTING

    The Company reports its financial performance based on three reportable segments, which are Performance Chemicals, Fuel Specialties and Oilfield Services.

    The Chief Operating Decision Maker (“CODM”) is the President and Chief Executive Officer (the Principal Executive Officer). The CODM evaluates the performance of the Company’s segments and makes strategic decisions relating to the Company's allocation of resources, based on the segments' gross profit and operating income.

    7


     

    The following table analyzes sales and other financial information by the Company’s reportable segments:

     

     

    Three Months Ended
    March 31,

     

    (in millions)

     

    2026

     

     

    2025

     

    Net Sales:

     

     

     

     

     

     

    Personal Care

     

    $

    97.1

     

     

    $

    100.6

     

    Home Care

     

     

    30.8

     

     

     

    26.3

     

    Other

     

     

    41.5

     

     

     

    41.5

     

    Performance Chemicals

     

     

    169.4

     

     

     

    168.4

     

    Refinery and Performance

     

     

    130.9

     

     

     

    129.4

     

    Other

     

     

    50.7

     

     

     

    40.9

     

    Fuel Specialties

     

     

    181.6

     

     

     

    170.3

     

    Oilfield Services

     

     

    102.2

     

     

     

    102.1

     

     

    $

    453.2

     

     

    $

    440.8

     

    Gross profit:

     

     

     

     

     

     

    Performance Chemicals

     

    $

    28.4

     

     

    $

    35.3

     

    Fuel Specialties

     

     

    64.3

     

     

     

    60.8

     

    Oilfield Services

     

     

    30.8

     

     

     

    29.0

     

    Total gross profit

     

    $

    123.5

     

     

    $

    125.1

     

    Operating income/(loss):

     

     

     

     

     

     

    Performance Chemicals

     

    $

    10.7

     

     

    $

    19.8

     

    Fuel Specialties

     

     

    37.8

     

     

     

    36.9

     

    Oilfield Services

     

     

    5.6

     

     

     

    4.1

     

    Corporate costs

     

     

    (22.3

    )

     

     

    (17.7

    )

    Adjustment to fair value of contingent consideration

     

     

    4.7

     

     

     

    (0.7

    )

    Profit on disposal of property, plant and equipment

     

     

    —

     

     

     

    0.1

     

    Total operating income

     

    $

    36.5

     

     

    $

    42.5

     

     

    The difference between net sales and gross profit is defined as cost of goods sold. The difference between segmental gross profit and operating income/(expense) is split between selling, general and administrative expenses and research and development expenses.

     


    The following table analyzes cost of goods sold by the Company’s reportable segments:

     

     

     

    Three Months Ended
    March 31,

     

    (in millions)

     

    2026

     

     

    2025

     

    Performance Chemicals

     

    $

    141.0

     

     

    $

    133.1

     

    Fuel Specialties

     

     

    117.3

     

     

     

    109.5

     

    Oilfield Services

     

     

    71.4

     

     

     

    73.1

     

    Total cost of goods sold

     

    $

    329.7

     

     

    $

    315.7

     

     

    The following table analyzes selling, general and administrative expenses and research and development expenses by the Company’s reportable segments:

     

     

     

    Three Months Ended
    March 31,

     

    (in millions)

     

    2026

     

     

    2025

     

    Performance Chemicals

     

    $

    17.7

     

     

    $

    15.5

     

    Fuel Specialties

     

     

    26.5

     

     

     

    23.9

     

    Oilfield Services

     

     

    25.2

     

     

     

    24.9

     

    Corporate

     

     

    22.3

     

     

     

    17.7

     

    Total selling, general and administrative expenses and research and development expenses

     

    $

    91.7

     

     

    $

    82.0

     

     

    8


     

    NOTE 3 – EARNINGS PER SHARE

    Basic earnings per share is based on the weighted average number of common shares outstanding during the period. Diluted earnings per share includes the effect of options that are dilutive and outstanding during the period under the treasury stock method. Per share amounts are computed as follows:

     

     

    Three Months Ended
    March 31,

     

     

    2026

     

     

    2025

     

    Numerator (in millions):

     

     

     

     

     

     

    Net income attributable to Innospec

     

    $

    30.4

     

     

    $

    32.8

     

    Denominator (in thousands):

     

     

     

     

     

     

    Weighted average common shares outstanding

     

     

    24,776

     

     

     

    24,970

     

    Dilutive effect of stock options and awards

     

     

    68

     

     

     

    132

     

    Denominator for diluted earnings per share

     

     

    24,844

     

     

     

    25,102

     

    Earnings per share, basic:

     

    $

    1.23

     

     

    $

    1.31

     

    Earnings per share, diluted:

     

    $

    1.22

     

     

    $

    1.31

     

     

    In the three months ended March 31, 2026, the average number of anti-dilutive options excluded from the calculation of diluted earnings per share were 23,519 (three months ended March 31, 2025– 10,342).

    NOTE 4 – GOODWILL

    The following table summarizes the goodwill movements in the year:

     

    (in millions)

     

    2026

     

    Opening balance at January 1

     

    $

    399.0

     

    Exchange effects

     

     

     

        Performance Chemicals

     

     

    0.1

     

        Fuel Specialties

     

     

    —

     

    Closing balance at March 31

     

    $

    399.1

     

     

    NOTE 5 – OTHER INTANGIBLE ASSETS

    The following table analyzes other intangible assets movements in the year:

     

    (in millions)

     

    2026

     

    Gross cost at January 1

     

    $

    373.3

     

    Additions

     

     

    5.1

     

    Exchange effect

     

     

    (2.1

    )

    Gross cost at March 31

     

     

    376.3

     

    Accumulated amortization at January 1

     

     

    (305.6

    )

    Amortization expense

     

     

    (2.6

    )

    Exchange effect

     

     

    0.8

     

    Accumulated amortization at March 31

     

     

    (307.4

    )

    Net book amount at March 31

     

     

    68.9

     

     

    The amortization expense for the three months ended March 31, 2026 was $2.6 million (three months ended March 31, 2025 – $2.7 million).

     

    9


     

    In 2026, we have capitalized $5.1 million in relation to the development of our internal-use software for a new Enterprise Resource Planning (“ERP”) system across all our regions. The project is now substantially complete. The expenses capitalized include the acquisition costs for the software as well as the external consultancy costs and the internal employee costs relating to software development.

    NOTE 6 – PENSION AND POST EMPLOYMENT BENEFITS

    The Company maintains an unfunded defined benefit pension plan covering certain current and former employees in Germany (the “German plan”). The German plan is closed to new entrants and has no assets. As at March 31, 2026, we have recorded a liability of $9.1 million (December 31, 2025 $9.4 million).

     

    The net periodic benefit/(cost) is shown in the following table:

     

     

    Three Months Ended
    March 31,

     

    (in millions)

     

    2026

     

     

    2025

     

    Service credit/(cost)

     

    $

    —

     

     

    $

    (1.2

    )

    Interest cost on projected benefit obligation

     

     

    (0.1

    )

     

     

    (0.1

    )

    Net periodic benefit/(cost)

     

    $

    (0.1

    )

     

    $

    (1.3

    )

     

    The prior year includes a service cost related to the now closed United Kingdom defined benefit pension scheme. The service cost has been recognized in selling, general and administrative expenses. All other items have been recognized within other income and expense.

    In addition, we have obligations for post-employment benefits in some of our other European businesses. As at March 31, 2026, we have recorded a liability of $3.7 million (December 31, 2025 $3.8 million).

    10


     

    NOTE 7 – INCOME TAXES

     

    As of January 1, 2026, the Company had no unrecognized tax benefits, and there has been no change in unrecognized tax benefits during the three months ended March 31, 2026. Accordingly, there was no accrual for uncertain tax positions as of March 31, 2026, and the Company recorded no associated interest or penalties. The Company does not expect any significant changes to this position over the next twelve months.

     

    As of March 31, 2026, the Company and its U.S. subsidiaries remain open to examination by the IRS for years 2022 onwards under the statute of limitations. The Company’s subsidiaries in foreign tax jurisdictions are open to examination including Brazil (2021 onwards), Germany (2021 onwards), and the U.K. (2024 onwards).

     

    NOTE 8 – LONG-TERM DEBT

    As at March 31, 2026, and December 31, 2025, the Company had not drawn down on its revolving credit facility. During the three months ended March 31, 2026 and 2025, the Company did not draw down or repay any borrowing on its revolving credit facility.

    The Company continues to have available a $250.0 million multicurrency revolving credit facility until May 30, 2028.

    11


     

    NOTE 9 – PLANT CLOSURE PROVISIONS

    The Company has continuing plans to remediate manufacturing facilities at sites around the world as and when those operations are expected to cease, or we are required to decommission the sites according to local laws and regulations. The liability for the estimated plant closure costs includes costs for asset retirement obligations and environmental remediation liabilities.

    The principal site giving rise to asset retirement obligations is the manufacturing site at Ellesmere Port in the U.K.. There are also asset retirement obligations and environmental remediation liabilities in respect of our other manufacturing sites, which are relatively insignificant.

     

    Movements in the provisions are summarized as follows:

     

    (in millions)

     

    2026

     

    Total at January 1

     

    $

    65.2

     

    Charge for the period

     

     

    2.3

     

    Utilized in the period

     

     

    (0.8

    )

    Exchange effect

     

     

    (1.0

    )

    Total at March 31

     

     

    65.7

     

    Due within one year

     

     

    (4.9

    )

    Due after one year

     

    $

    60.8

     

     

    The charge for the three months ended March 31, 2026, was $2.3 million (three months ended March 31, 2025 $0.8 million). The current year charge represents the accounting accretion and a $1.4 million increase to the provisions for legacy operations in the United Kingdom. Amounts due within one year refer to provisions where expenditure is expected to arise within one year of the balance sheet date.

    12


     

    NOTE 10 – FAIR VALUE MEASUREMENTS

    The following table presents the carrying amount and fair values of the Company’s financial assets and liabilities measured on a recurring basis:

     

     

    March 31, 2026

     

     

    December 31, 2025

     

    (in millions)

     

    Carrying
    Amount

     

     

    Fair
    Value

     

     

    Carrying
    Amount

     

     

    Fair
    Value

     

    Assets

     

     

     

     

     

     

     

     

     

     

     

     

    Derivatives (Level 1 measurement):

     

     

     

     

     

     

     

     

     

     

     

     

    Other current and non-current assets:

     

     

     

     

     

     

     

     

     

     

     

     

    Emissions Trading Scheme credits

     

     

    1.9

     

     

     

    1.9

     

     

     

    3.2

     

     

     

    3.2

     

    Foreign currency forward exchange contracts

     

     

    4.2

     

     

     

    4.2

     

     

     

    3.4

     

     

     

    3.4

     

    Liabilities

     

     

     

     

     

     

     

     

     

     

     

     

    Non-financial liabilities (Level 3 measurement):

     

     

     

     

     

     

     

     

     

     

     

     

    Acquisition-related contingent consideration

     

     

    4.0

     

     

     

    4.0

     

     

     

    8.3

     

     

     

    8.3

     

     

    The following methods and assumptions were used to estimate the fair values:

    Emissions Trading Scheme credits: The fair value is determined by the open market pricing at the end of the reporting period.

    Foreign currency forward exchange contracts: The fair value of derivatives relating to foreign currency forward exchange contracts are derived from current settlement prices and comparable contracts using current assumptions. Foreign currency forward exchange contracts primarily relate to contracts entered into to hedge future known transactions or hedge balance sheet net cash positions. The movements in the carrying amounts and fair values of these contracts are largely due to changes in exchange rates against the U.S. dollar.

    Acquisition-related contingent consideration: Contingent consideration payable in cash is discounted to its fair value at each balance sheet date. Where contingent consideration is dependent upon pre-determined financial targets, an estimate of the fair value of the likely consideration payable is made at each balance sheet date. The contingent consideration payable has been calculated based on the latest forecast. The movement in the current year relates to a $4.9 million reduction in the fair value of the expected payable relating to the acquisition of QGP Química Geral (“QGP”), partially offset by an accretion charge of $0.2 million and the impact of foreign exchange of $0.4 million.

    NOTE 11 – DERIVATIVE INSTRUMENTS AND RISK MANAGEMENT

    The Company enters into various foreign currency forward exchange contracts to minimize currency exchange rate exposure from expected future cash flows. As at March 31, 2026, the contracts have maturity dates of up to two years at the date of inception. These foreign currency forward exchange contracts have not been designated as hedging instruments, and their impact on the income statement for the three months ended March 31, 2026 was a gain of $1.9 million (three months ended March 31, 2025 a loss of $2.3 million). The gain or loss has been recorded in other income or expense.

    13


     

    NOTE 12 – CONTINGENCIES

    Legal matters

    We are involved from time to time in claims and legal proceedings that result from, and are incidental to, the conduct of our business including business and commercial litigation, and employee and product liability claims.

    As reported in our Annual Report on Form 10-K for the year ended December 31, 2023 (the “2023 Form 10-K"), we have incurred financial losses and lodged a civil and criminal legal claim related to a misappropriation of inventory in Brazil. At the time of filing, there have been no significant developments to report in relation to the claims being made. Consistent with prior quarters, a corresponding asset for the potential legal or insurance recoveries has not been recorded for the resulting financial losses arising from this matter.

    In addition, unrelated to the Brazil matter, in the unlikely event there are an unexpectedly large number of individual claims or proceedings with an adverse resolution, this could in the aggregate have a material adverse effect on the results of operations for a particular year or quarter.

    Guarantees

    The Company and certain of the Company’s consolidated subsidiaries are contingently liable for certain obligations of affiliated companies primarily in the form of guarantees of debt and performance under contracts entered into as a normal business practice. This includes guarantees of non-U.S. excise taxes and customs duties. As at March 31, 2026, such guarantees, which are not recognized as liabilities in the condensed consolidated financial statements, amounted to $6.1 million (December 31, 2025 $6.0 million). The remaining terms of the fixed maturity guarantees are up to 7 years, with some further guarantees having no fixed expiry date.

    Under the terms of the guarantee arrangements, generally the Company would be required to perform the obligations should the affiliated company fail to fulfill its obligations under the arrangements. In some cases, the guarantee arrangements have recourse provisions that would enable the Company to recover any payments made under the terms of the guarantees from securities held of the guaranteed parties’ assets.

    The Company and its affiliates have numerous long-term sales and purchase commitments in their various business activities, which are expected to be fulfilled with no adverse consequences material to the Company.

    14


     

    NOTE 13 – STOCK-BASED COMPENSATION PLANS

    The following table summarizes the transactions of the Company’s share-based compensation for 2026 and 2025:

     

     

    Three Months Ended
    March 31,

     

    (in millions)

     

    2026

     

     

    2025

     

    Stock options

     

    $

    1.8

     

     

    $

    1.9

     

    Stock equivalent units

     

     

    0.1

     

     

     

    0.2

     

    Total

     

    $

    1.9

     

     

    $

    2.1

     

    The following table summarizes the transactions of the Company’s share-based compensation plans for the three months ended March 31, 2026.

     

     

    Number of
    shares

     

     

    Weighted
    Average
    Grant-Date
    Fair Value

     

    Nonvested at December 31, 2025

     

     

    431,297

     

     

    $

    109.5

     

    Granted

     

     

    207,459

     

     

    $

    76.9

     

    Vested

     

     

    (135,600

    )

     

    $

    92.7

     

    Forfeited

     

     

    —

     

     

    $

    —

     

    Nonvested at March 31, 2026

     

     

    503,156

     

     

    $

    100.6

     

     

    For the awards granted with market conditions, a Monte Carlo model has been used to calculate the grant-date fair value. For all other awards granted, a fair market value methodology has been used to calculate the grant-date fair value.

    The awards granted with market and non-market conditions include performance measures that can result in a maximum 200% vesting for the number of stock options granted. The predicted vesting has been reflected in the grant-date fair value calculation, but has not been reflected for the number of awards granted, as shown in the table above.

    As of March 31, 2026, there was $28.3 million of total unrecognized compensation cost related to nonvested share-based compensation arrangements. That cost is expected to be recognized over a weighted-average period of 2.3 years.

    15


     

    NOTE 14 – RECLASSIFICATIONS OUT OF ACCUMULATED OTHER COMPREHENSIVE LOSS

    There were no reclassifications out of accumulated other comprehensive loss (“AOCL”) for the three months ended March 31, 2026.

     

    Changes in AOCL for the three months ended March 31, 2026, net of tax, were:

     

    (in millions)

     

    Defined
    Benefit
    Pension
    Plan Items

     

     

    Cumulative
    Translation
    Adjustments

     

     

    Total

     

    Balance at December 31, 2025

     

    $

    0.9

     

     

    $

    (35.6

    )

     

    $

    (34.7

    )

    Other comprehensive income/(loss) before reclassifications

     

     

    —

     

     

     

    (6.1

    )

     

     

    (6.1

    )

    Amounts reclassified from AOCL

     

     

    —

     

     

     

    —

     

     

     

    —

     

    Total other comprehensive income/(loss)

     

     

    —

     

     

     

    (6.1

    )

     

     

    (6.1

    )

    Balance at March 31, 2026

     

    $

    0.9

     

     

    $

    (41.7

    )

     

    $

    (40.8

    )

     

     

    There were no reclassifications out of AOCL for the three months ended March 31, 2025.

    Changes in AOCL for the three months ended March 31, 2025, net of tax, were:

     

    (in millions)

     

    Defined
    Benefit
    Pension
    Plan Items

     

     

    Cumulative
    Translation
    Adjustments

     

     

    Total

     

    Balance at December 31, 2024

     

    $

    —

     

     

    $

    (91.0

    )

     

    $

    (91.0

    )

    Other comprehensive income/(loss) before reclassifications

     

     

    —

     

     

     

    18.7

     

     

     

    18.7

     

    Amounts reclassified from AOCL

     

     

    —

     

     

     

    —

     

     

     

    —

     

    Total other comprehensive income/(loss)

     

     

    —

     

     

     

    18.7

     

     

     

    18.7

     

    Balance at March 31, 2025

     

    $

    —

     

     

    $

    (72.3

    )

     

    $

    (72.3

    )

     

    NOTE 15 – RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS

     

    There have been no recently issued accounting pronouncements.

     

    NOTE 16 – RELATED PARTY TRANSACTIONS

    Mr. David F. Landless has been a non-executive director of the Company since January 1, 2016 and is a non-executive director of Ausurus Group Limited which owns European Metal Recycling Limited (“EMR”) which from time to time purchases scrap metal from the Company. The Company has sold less than $0.1 million of scrap metal to EMR in the three months ended March 31, 2026 (three months ended March 31, 2025 nil). A tendering process is operated periodically to select the best buyer for the sale of scrap metal by the Company. As at March 31, 2026, EMR owed nil for scrap metal purchased from the Company (December 31, 2025 nil).

    16


     

    Item 2 Management’s Discussion and Analysis of Financial Condition and Results of Operations for the Three Months Ended March 31, 2026

    This discussion should be read in conjunction with our unaudited interim condensed consolidated financial statements and the notes thereto.

    CRITICAL ACCOUNTING ESTIMATES

    The policies and estimates that the Company considers the most critical in terms of complexity and subjectivity of assessment are those related to plant closure provisions, goodwill, other intangible assets and property, plant and equipment. These policies have been discussed in the Company’s 2025 Form 10-K.

    RESULTS OF OPERATIONS

    The Company reports its financial performance based on three reportable segments, which are Performance Chemicals, Fuel Specialties and Oilfield Services.

    The following table provides sales, gross profit and operating income by reporting segment:

     

     

    Three Months Ended
    March 31,

     

    (in millions)

     

    2026

     

     

    2025

     

    Net sales:

     

     

     

     

     

     

    Performance Chemicals

     

    $

    169.4

     

     

    $

    168.4

     

    Fuel Specialties

     

     

    181.6

     

     

     

    170.3

     

    Oilfield Services

     

     

    102.2

     

     

     

    102.1

     

     

    $

    453.2

     

     

    $

    440.8

     

    Gross profit:

     

     

     

     

     

     

    Performance Chemicals

     

    $

    28.4

     

     

    $

    35.3

     

    Fuel Specialties

     

     

    64.3

     

     

     

    60.8

     

    Oilfield Services

     

     

    30.8

     

     

     

    29.0

     

     

    $

    123.5

     

     

    $

    125.1

     

    Operating income/(loss):

     

     

     

     

     

     

    Performance Chemicals

     

    $

    10.7

     

     

    $

    19.8

     

    Fuel Specialties

     

     

    37.8

     

     

     

    36.9

     

    Oilfield Services

     

     

    5.6

     

     

     

    4.1

     

    Corporate costs

     

     

    (22.3

    )

     

     

    (17.7

    )

    Adjustment to fair value of contingent consideration

     

     

    4.7

     

     

     

    (0.7

    )

    Profit on disposal of property, plant and equipment

     

     

    —

     

     

     

    0.1

     

    Total operating income

     

    $

    36.5

     

     

    $

    42.5

     

     

    17


     

    Three Months Ended March 31, 2026

    The following table shows the changes in sales, gross profit and operating expenses by reporting segment for the three months ended March 31, 2026, and the three months ended March 31, 2025:

     

     

    Three Months Ended
    March 31,

     

     

     

     

     

     

    (in millions, except ratios)

     

    2026

     

     

    2025

     

     

    Change

     

     

     

    Net sales:

     

     

     

     

     

     

     

     

     

     

     

    Performance Chemicals

     

    $

    169.4

     

     

    $

    168.4

     

     

    $

    1.0

     

     

    +1%

    Fuel Specialties

     

     

    181.6

     

     

     

    170.3

     

     

     

    11.3

     

     

    +7%

    Oilfield Services

     

     

    102.2

     

     

     

    102.1

     

     

     

    0.1

     

     

    +0%

     

    $

    453.2

     

     

    $

    440.8

     

     

    $

    12.4

     

     

    +3%

    Gross profit:

     

     

     

     

     

     

     

     

     

     

     

    Performance Chemicals

     

    $

    28.4

     

     

    $

    35.3

     

     

    $

    (6.9

    )

     

    -20%

    Fuel Specialties

     

     

    64.3

     

     

     

    60.8

     

     

     

    3.5

     

     

    +6%

    Oilfield Services

     

     

    30.8

     

     

     

    29.0

     

     

     

    1.8

     

     

    +6%

     

    $

    123.5

     

     

    $

    125.1

     

     

    $

    (1.6

    )

     

    -1%

    Gross margin (%):

     

     

     

     

     

     

     

     

     

     

     

    Performance Chemicals

     

     

    16.8

     

     

     

    21.0

     

     

     

    -4.2

     

     

     

    Fuel Specialties

     

     

    35.4

     

     

     

    35.7

     

     

     

    -0.3

     

     

     

    Oilfield Services

     

     

    30.1

     

     

     

    28.4

     

     

     

    +1.7

     

     

     

    Aggregate

     

     

    27.3

     

     

     

    28.4

     

     

     

    -1.1

     

     

     

    Operating expenses:

     

     

     

     

     

     

     

     

     

     

     

    Performance Chemicals

     

    $

    (17.7

    )

     

    $

    (15.5

    )

     

    $

    (2.2

    )

     

    +14%

    Fuel Specialties

     

     

    (26.5

    )

     

     

    (23.9

    )

     

     

    (2.6

    )

     

    +11%

    Oilfield Services

     

     

    (25.2

    )

     

     

    (24.9

    )

     

     

    (0.3

    )

     

    +1%

    Corporate costs

     

     

    (22.3

    )

     

     

    (17.7

    )

     

     

    (4.6

    )

     

    +26%

    Adjustment to fair value of contingent consideration

     

     

    4.7

     

     

     

    (0.7

    )

     

     

    5.4

     

     

    n/a

    Profit on disposal of property, plant and equipment

     

     

    —

     

     

     

    0.1

     

     

     

    (0.1

    )

     

    n/a

     

    $

    (87.0

    )

     

    $

    (82.6

    )

     

    $

    (4.4

    )

     

    +5%

     

    Performance Chemicals

    Net sales: the table below details the components which comprise the year over year change in net sales spread across the markets in which we operate:

     

     

    Three Months Ended March 31, 2026

     

    Change (%)

     

    Americas

     

     

    EMEA

     

     

    ASPAC

     

     

    Total

     

    Volume

     

     

    -15

     

     

     

    -1

     

     

     

    -31

     

     

     

    -9

     

    Price and product mix

     

     

    +6

     

     

     

    -3

     

     

     

    +1

     

     

     

    +1

     

    Exchange rates

     

     

    —

     

     

     

    +17

     

     

     

    +3

     

     

     

    +9

     

     

     

    -9

     

     

     

    +13

     

     

     

    -27

     

     

     

    +1

     

     

    Volumes for the Americas were lower due to reduced demand for our personal care products, partly offset by a favorable price and product mix due to pricing improvements. Volumes in EMEA were lower, combined with an adverse price and product mix driven by higher demand for lower priced products. ASPAC volumes were lower driven by decreased demand for our personal care products, slightly offset by a favorable price and product mix. EMEA and ASPAC benefited from favorable foreign currency exchange rate movements.

    Gross margin: the year over year decrease of 4.2 percentage points was primarily due to an adverse sales mix, together with the negative manufacturing variances in North America due to lower production volumes following severe weather conditions at the start of the quarter.

    18


     

    Operating expenses: the year over year increase of $2.2 million year over year was primarily due to adverse movements to the provisions for doubtful debts driven by our aged debtor accounting policy, together with increased research and development expenses.

    Fuel Specialties

    Net sales: the table below details the components which comprise the year over year change in net sales spread across the markets in which we operate:

     

     

    Three Months Ended March 31, 2026

     

    Change (%)

     

    Americas

     

     

    EMEA

     

     

    ASPAC

     

     

    AvGas

     

     

    Total

     

    Volume

     

     

    +14

     

     

     

    +7

     

     

     

    +9

     

     

     

    -7

     

     

     

    +10

     

    Price and product mix

     

     

    -16

     

     

     

    -7

     

     

     

    -6

     

     

     

    +30

     

     

     

    -9

     

    Exchange rates

     

     

    +1

     

     

     

    +13

     

     

     

    +2

     

     

     

    —

     

     

     

    +6

     

     

     

    -1

     

     

     

    +13

     

     

     

    +5

     

     

     

    +23

     

     

     

    +7

     

     

    Sales volumes in all our regions increased year over year due to increased demand from customers. All our regions were impacted by an adverse price and product mix due to higher sales of lower priced products. AvGas volumes were lower than the prior year due to variations in the demand from customers, being offset by a favorable customer mix. EMEA and ASPAC benefited from favorable foreign currency exchange rate movements.

    Gross margin: the year over year decrease of 0.3 percentage points was due to an adverse sales mix from increased sales of lower margin products.

    Operating expenses: the year over year increase of $2.6 million was primarily due to adverse movements to the provisions for doubtful debts driven by our aged debtor accounting policy, together with increased administrative expenses.

    Oilfield Services

    Net sales: have increased year over year by $0.1 million. Sales in the Americas were higher year over year, being partly outweighed by lower sales in EMEA. The majority of our customer activity is concentrated in the Americas region.

    Gross margin: the year over year increase of 1.7 percentage points was due to a favorable sales mix.

    Operating expenses: the year over year increase of $0.3 million was primarily due to higher selling expenses.

    Other Income Statement Captions

    Corporate costs: the year over year increase of $4.6 million was primarily due to higher legacy costs of closed operations, an adverse revaluation for the U.K. emissions trading scheme carbon credits, higher legal and compliance expenses and additional amortization for the new ERP system.

    Adjustment to fair value of contingent consideration: is a credit in the current year of $4.7 million compared to an expense in the prior year of $0.7 million. The adjustment relates to the acquisition of QGP within our Performance Chemicals segment. See Note 10 of the Notes to the Condensed Consolidated Financial Statements for additional information.

    19


     

    Other net income/(expense): for the three months ended March 31, 2026 and 2025, included the following:

     

    (in millions)

     

    2026

     

     

    2025

     

     

    Change

     

    Net pension credit/(cost)

     

    $

    (0.1

    )

     

    $

    (0.1

    )

     

    $

    —

     

    Foreign exchange gains/(losses) on translation

     

     

    0.8

     

     

     

    2.7

     

     

     

    (1.9

    )

    Foreign currency forward contracts gains/(losses)

     

     

    1.9

     

     

     

    (2.3

    )

     

     

    4.2

     

     

    $

    2.6

     

     

    $

    0.3

     

     

    $

    2.3

     

     

    Interest income/(expense), net: in the three months ended March 31, 2026 was $0.8 million of income compared to $2.4 million of income in the three months ended March 31, 2025, driven by lower interest rates and lower cash balances in the current year.

     

    Income taxes: the effective tax rate was 22.8% and 25.7% in the first quarter of 2026 and 2025, respectively. The adjusted effective tax rate, once adjusted for the items set out in the following table, was 22.9% in 2026 compared with 24.0% in 2025. The 1.1% decrease in the adjusted effective rate was primarily due to the fact that a higher proportion of the Company’s profits are being generated in lower tax jurisdictions. The Company believes that this adjusted effective tax rate, a non-GAAP financial measure, provides useful information to investors and may assist them in evaluating the Company’s underlying performance and identifying operating trends. In addition, management uses this non-GAAP financial measure internally to evaluate the performance of the Company’s operations and for planning and forecasting in subsequent periods.

    The following table shows a reconciliation of the GAAP effective tax charge to the adjusted effective tax charge:

     

     

    Three Months Ended
    March 31,

     

    (in millions)

     

    2026

     

     

    2025

     

    Income before income taxes

     

    $

    39.9

     

     

    $

    45.2

     

    Adjustment for stock compensation

     

     

    1.8

     

     

     

    2.0

     

    Adjustment to fair value of contingent consideration

     

     

    (4.7

    )

     

     

    0.7

     

    Legacy costs of closed operations

     

     

    2.3

     

     

     

    0.8

     

    Adjusted income before income taxes

     

    $

    39.3

     

     

    $

    48.7

     

    Income taxes

     

    $

    9.1

     

     

    $

    11.6

     

    Tax on stock compensation

     

     

    (0.7

    )

     

     

    (0.1

    )

    Tax on adjustment to fair value of contingent consideration

     

     

    —

     

     

     

    —

     

    Tax on legacy cost of closed operations

     

     

    0.6

     

     

     

    0.2

     

    Adjusted income taxes

     

    $

    9.0

     

     

    $

    11.7

     

    GAAP effective tax rate

     

     

    22.8

    %

     

     

    25.7

    %

    Adjusted effective tax rate

     

     

    22.9

    %

     

     

    24.0

    %

     

     

    20


     

    LIQUIDITY AND FINANCIAL CONDITION

    Working Capital

    In the three months ended March 31, 2026 our working capital increased by $19.8 million, while our adjusted working capital increased by $20.1 million. The difference is primarily due to the exclusion of the movements for cash and cash equivalents together with the changes for taxes, being partly offset by the change in the value of acquisition-related contingent consideration.

    The Company believes that adjusted working capital, a non-GAAP financial measure (defined by the Company as trade and other accounts receivable, inventories, prepaid expenses, accounts payable and accrued liabilities rather than total current assets less total current liabilities) provides useful information to investors in evaluating the Company’s underlying performance and identifying operating trends. Management uses this non-GAAP financial measure internally to allocate resources and evaluate the performance of the Company’s operations. Items excluded from working capital in the adjusted working capital calculation are listed in the table below and represent factors which do not fluctuate in line with the day to day working capital needs of the business.

     

    (in millions)

     

    March 31,
    2026

     

     

    December 31,
    2025

     

    Total current assets

     

    $

    999.1

     

     

    $

    1,004.6

     

    Total current liabilities

     

     

    (334.8

    )

     

     

    (360.1

    )

    Working capital

     

     

    664.3

     

     

     

    644.5

     

    Less cash and cash equivalents

     

     

    (289.1

    )

     

     

    (292.5

    )

    Less prepaid income taxes

     

     

    (10.6

    )

     

     

    (13.1

    )

    Less other current assets

     

     

    (6.8

    )

     

     

    (7.3

    )

    Add back accrued income taxes

     

     

    4.3

     

     

     

    5.3

     

    Add back current portion of plant closure provisions

     

     

    4.9

     

     

     

    4.9

     

    Add back current portion of acquisition-related contingent consideration

     

     

    2.7

     

     

     

    7.0

     

    Add back current portion of operating lease liabilities

     

     

    15.1

     

     

     

    15.9

     

    Adjusted working capital

     

    $

    384.8

     

     

    $

    364.7

     

     

    We had a $11.9 million increase in trade and other accounts receivable, including a $2.4 million increase in allowances, which was primarily due to increased sales for our Fuel Specialties and Oilfield Services segments. Days’ sales outstanding decreased in our Performance Chemicals segment from 72 days to 66 days; increased from 57 days to 59 days in our Fuel Specialties segment; and increased from 64 days to 68 days in our Oilfield Services segment.

    We had a $7.8 million decrease in inventories, including a $1.0 million decrease in allowances, which was driven by lower levels of raw materials in our Performance Chemicals and Fuel Specialties segments. The Company continues to maintain inventory levels necessary to manage the risk of potential supply chain disruption for certain key raw materials, especially in our Fuel Specialties segment. Days’ sales in inventory in our Performance Chemicals segment decreased from 65 days to 58 days; decreased from 184 days to 132 days in our Fuel Specialties segment; and decreased from 83 days to 64 days in our Oilfield Services segment.

    Prepaid expenses decreased $3.2 million, from $20.1 million to $16.9 million, primarily due to the cyclical expensing of prepaid invoices.

    We had a $19.2 million decrease in accounts payable and accrued liabilities, which was dependent on the timing of payments for each of our reporting segments. Creditor days (including goods received not invoiced) have decreased in our Performance Chemicals segment from 50 days to 47 days; decreased from 58 days to 52 days in our Fuel Specialties segment; and increased from 46 days to 47 days in our Oilfield Services segment. The changes for creditor days are impacted by the timing of sales and cost of sales in the quarter, when using a countback methodology.

    21


     

     

    Operating Cash Flows

    We generated cash from operating activities of $17.6 million in the three months ended March 31, 2026 compared to $28.3 million in the three months ended March 31, 2025. The decrease in cash generated from operating activities was primarily related to decreased operating income after adjusting for the changes to the fair value of contingent consideration, together with the timing of income tax payments.

    Cash

    At March 31, 2026 and December 31, 2025, we had cash and cash equivalents of $289.1 million and $292.5 million, respectively, of which $120.6 million and $145.4 million, respectively, were held by non-U.S. subsidiaries principally in the United Kingdom.

    The decrease in cash and cash equivalents of $3.4 million for the three months ended March 31, 2026 was primarily driven by our continued investments in capital projects, payments for our new ERP system implementation and the repurchases of our common stock, being partly offset by the cash generated from operating activities.

    Debt

    We continue to have available a $250.0 million multicurrency revolving credit facility.

    At March 31, 2026, and December 31, 2025, we had no debt outstanding under the revolving credit facility and no obligations were outstanding under finance leases. See Note 8 of the Notes to the Condensed Consolidated Financial Statements for additional information.

     

    22


     

    Item 3 Quantitative and Qualitative Disclosures about Market Risk

    The Company uses floating rate debt to finance its global operations. The Company is subject to business risks inherent in non-U.S. activities, including political and economic uncertainty, import and export limitations, and market risk related to changes in interest rates and foreign currency exchange rates. The political and economic risks are mitigated by the stability of the major countries in which the Company’s largest operations are located. Credit limits, ongoing credit evaluation and account monitoring procedures are used to minimize bad debt risk. Collateral is not generally required.

    From time to time, the Company uses derivatives, including interest rate swaps, commodity swaps and foreign currency forward exchange contracts, in the normal course of business to manage market risks. The derivatives used in hedging activities are considered risk management tools and are not used for trading purposes. In addition, the Company enters into derivative instruments with a diversified group of major financial institutions in order to manage the exposure to non-performance of such instruments. The Company’s objective in managing the exposure to changes in interest rates is to limit the impact of such changes on earnings and cash flows and to lower overall borrowing costs. The Company’s objective in managing the exposure to changes in foreign currency exchange rates is to reduce volatility on earnings and cash flows associated with such changes.

    The Company offers fixed prices for some long-term sales contracts. As manufacturing and raw material costs are subject to variability, the Company, from time to time, uses commodity swaps to hedge the cost of some raw materials thus reducing volatility on earnings and cash flows. The derivatives are considered risk management tools and are not used for trading purposes. The Company’s objective is to manage its exposure to fluctuating costs of raw materials.

    The Company’s exposure to market risk has been discussed in the 2025 Form 10-K and there have been no significant changes since that time.

    Item 4 Controls and Procedures

    Evaluation of Disclosure Controls and Procedures

    Based on an evaluation carried out as of the end of the period covered by this report, under the supervision and with the participation of our management, our Chief Executive Officer and our Chief Financial Officer concluded that the Company’s “disclosure controls and procedures” (as defined in Rules 13a-15(e) and 15d-15(e) of the Securities Exchange Act of 1934) were effective as of March 31, 2026, to provide reasonable assurance that information required to be disclosed by the Company in reports that it files or submits under the Exchange Act is (i) recorded, processed, summarized and reported within the time periods specified in the SEC rules and forms and (ii) accumulated and communicated to the Company’s management, including its principal executive officer and principal financial officer, as appropriate to allow timely decisions regarding required disclosure.

    Changes in Internal Control over Financial Reporting

    The Company is continuously seeking to improve the efficiency and effectiveness of its operations and of its internal control over financial reporting. This is intended to result in refinements to processes throughout the Company.

    As previously disclosed, we have been developing a new information system platform which began in 2022. The new platform provider is well established in the market. The implementation has been a phased, risk-managed, site deployment following a multistage user acceptance program and the implementation is now substantially complete. In connection with this implementation, the Company has updated its internal controls over financial reporting, as necessary, to accommodate modifications to its business processes and accounting procedures.

    23


     

    There were no changes to our internal control over financial reporting which were identified in connection with the evaluation required by paragraph (d) of Rules 13a-15 and 15d-15 under the Securities Exchange Act of 1934, that have materially affected, or are reasonably likely to materially affect, the Company’s internal control over financial reporting.

    24


     

    PART II OTHER INFORMATION

    Item 1 Legal Proceedings

    Legal matters

    We are involved from time to time in claims and legal proceedings that result from, and are incidental to, the conduct of our business including business and commercial litigation, employee and product liability claims.

    As reported in our 2023 Form 10-K, we have incurred financial losses and lodged a civil and criminal legal claim related to a misappropriation of inventory in Brazil. At the time of filing, there have been no significant developments to report in relation to the claims being made. Consistent with prior quarters, a corresponding asset for the potential legal or insurance recoveries has not been recorded for the resulting financial losses arising from this matter.

    In addition, unrelated to the Brazil matter, in the unlikely event there are an unexpectedly large number of individual claims or proceedings with an adverse resolution, this could in the aggregate have a material adverse effect on the results of operations for a particular year or quarter.

    Item 1A Risk Factors

    Information regarding risk factors that could have a material impact on our results of operations or financial condition are described under “Risk Factors” in Item 1A of Part I of our 2025 Form 10-K. In management’s view, there have been no material changes in the risk factors facing the Company as disclosed in those SEC filings.

    Item 2 Unregistered Sales of Equity Securities and Use of Proceeds

    There have been no unregistered sales of equity securities.

     

    On March 10, 2025, the Company announced a repurchase program which allows for up to $50 million of the Company’s common stock to be repurchased in the open market over a three-year period commencing on March 10, 2025.

     

    On May 7, 2026, the Company announced a new repurchase program which allows for up to $75 million of the Company’s common stock to be repurchased in the open market over a three-year period commencing on May 12, 2026. This replaces the $50 million repurchase authorization announced on March 10, 2025.

     

    The company also repurchases its common stock in connection with the exercising of stock options by directors and employees. The following table provides information about our repurchases of equity securities in the three months ended March 31, 2026.

     

    Period

     

    Total number
    of shares
    purchased

     

     

    Average price
    paid per share

     

     

    Total number of
    shares purchased
    as part of publicly
    announced plans or
    programs

     

     

    Approximate dollar
    value of shares that
    may yet be purchased
    under the plans or
    programs

    February 1, 2026 through February 28, 2026

     

     

    9,408

     

     

    $

    78.3

     

     

     

    —

     

     

    $

    27.8

     

    million

    March 1, 2026 through March 31, 2026

     

     

    90,000

     

     

    $

    69.3

     

     

     

    90,000

     

     

    $

    21.6

     

    million

    Total

     

     

    99,408

     

     

    $

    70.2

     

     

     

    90,000

     

     

    $

    21.6

     

    million

     

    25


     

    Item 3 Defaults Upon Senior Securities

    None.

    Item 4 Mine Safety Disclosures

    Not applicable.

    Item 5 Other Information

    (a), (b), and (c) – None.

    26


     

    Item 6 Exhibits

     

     

    31.1

     

    Certification of Chief Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

    31.2

     

    Certification of Chief Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

    32.1

     

    Certification of Chief Executive Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

    32.2

     

    Certification of Chief Financial Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

    101

     

    XBRL Instance Document and Related Item - The instance document does not appear in the interactive data file because its XBRL tags are embedded within the inline XBRL document.

    104

     

    Cover Page Interactive Data File – The cover page XBRL tags are embedded within the inline XBRL document.

     

    27


     

    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

     

     

     

     

    INNOSPEC INC.

     

    Registrant

     

     

     

     

    Date: May 8, 2026

    By

     

     /s/ PATRICK S. WILLIAMS

     

     

     

    Patrick S. Williams

    President and Chief Executive Officer

     

     

     

     

    Date: May 8, 2026

    By

     

    /s/ IAN P. CLEMINSON

     

     

     

    Ian P. Cleminson

    Executive Vice President and Chief Financial Officer

     

    28


    Get the next $IOSP alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $IOSP

    DatePrice TargetRatingAnalyst
    4/21/2025$115.00Neutral → Buy
    Seaport Research Partners
    3/30/2022Neutral
    Seaport Research Partners
    More analyst ratings

    $IOSP
    SEC Filings

    View All

    Innospec Inc. filed SEC Form 8-K: Leadership Update

    8-K - INNOSPEC INC. (0001054905) (Filer)

    6/4/26 4:31:12 PM ET
    $IOSP
    Major Chemicals
    Industrials

    SEC Form SD filed by Innospec Inc.

    SD - INNOSPEC INC. (0001054905) (Filer)

    5/29/26 6:03:18 AM ET
    $IOSP
    Major Chemicals
    Industrials

    Innospec Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

    8-K - INNOSPEC INC. (0001054905) (Filer)

    5/13/26 6:00:29 AM ET
    $IOSP
    Major Chemicals
    Industrials

    $IOSP
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Innospec Reports First Quarter 2026 Financial Results

    Continued strength in Fuel Specialties offset negative US winter storm impacts in other businesses Increasing confidence for sequential operating income and margin growth in Performance Chemicals and Oilfield Services Dividend increased by 10 percent; $6.2 million in share repurchases made in the quarter New $75 million buyback authorization GAAP EPS of $1.22 and adjusted non-GAAP EPS of $1.05 ENGLEWOOD, Colo., May 07, 2026 (GLOBE NEWSWIRE) -- Innospec Inc. (NASDAQ:IOSP) today announced its financial results for the first quarter ended March 31, 2026.   The Company declared its semi-annual dividend of 92 cents per common share for the first half of this year, representing an increase

    5/7/26 4:45:00 PM ET
    $IOSP
    Major Chemicals
    Industrials

    Innospec Schedules First Quarter 2026 Earnings Release and Conference Call

    ENGLEWOOD, Colo., April 07, 2026 (GLOBE NEWSWIRE) -- Innospec Inc. (NASDAQ:IOSP) today announced that it will release first quarter 2026 earnings results on Thursday, May 7, 2026 after market close. Following the release of its results, Patrick S. Williams, President and Chief Executive Officer, and Ian Cleminson, Executive Vice President and Chief Financial Officer, will host an interactive conference call on Friday, May 8, 2026, at 9:00 a.m. ET. The public is invited to listen to the conference call by registering in advance using the below Online Registration Link.   Upon registering, each participant will receive an email confirmation with dial-in numbers and a unique Personal PIN whi

    4/7/26 4:45:00 PM ET
    $IOSP
    Major Chemicals
    Industrials

    Innospec Reports Fourth Quarter and Full Year 2025 Financial Results

    Continued strength in Fuel Specialties with 7 percent operating income growth and improved margins Sequentially improving results in Performance Chemicals and Oilfield Services Excellent quarterly cash flow of $61.4 million generated from operations; Net cash improves to $292.5 million GAAP EPS $1.91 and adjusted non-GAAP EPS $1.50 ENGLEWOOD, Colo., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Innospec Inc. (NASDAQ:IOSP) today announced its financial results for the fourth quarter and full year ended December 31, 2025. Total revenues for the fourth quarter were $455.6 million, a decrease of 2 percent from $466.8 million in the corresponding period last year. Net income for the quarter was $47.4

    2/17/26 4:45:00 PM ET
    $IOSP
    Major Chemicals
    Industrials

    $IOSP
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Amendment: Director Blackmore Milton C sold $45,473 worth of shares (594 units at $76.55), decreasing direct ownership by 5% to 10,530 units (SEC Form 4)

    4/A - INNOSPEC INC. (0001054905) (Issuer)

    3/6/26 7:47:31 PM ET
    $IOSP
    Major Chemicals
    Industrials

    Amendment: Director Padfield Larry sold $45,473 worth of shares (594 units at $76.55), decreasing direct ownership by 6% to 9,453 units (SEC Form 4)

    4/A - INNOSPEC INC. (0001054905) (Issuer)

    3/6/26 7:41:11 PM ET
    $IOSP
    Major Chemicals
    Industrials

    Amendment: Director Poccia Claudia sold $9,110 worth of shares (119 units at $76.56), decreasing direct ownership by 2% to 6,508 units (SEC Form 4)

    4/A - INNOSPEC INC. (0001054905) (Issuer)

    3/6/26 5:34:53 PM ET
    $IOSP
    Major Chemicals
    Industrials

    $IOSP
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Parrette Leslie J bought $25,191 worth of shares (340 units at $74.09), increasing direct ownership by 6% to 5,837 units (SEC Form 4)

    4 - INNOSPEC INC. (0001054905) (Issuer)

    11/17/25 6:07:02 PM ET
    $IOSP
    Major Chemicals
    Industrials

    Director Parrette Leslie J bought $15,135 worth of shares (143 units at $105.84), increasing direct ownership by 3% to 4,734 units (SEC Form 4)

    4 - INNOSPEC INC. (0001054905) (Issuer)

    8/14/24 6:31:38 PM ET
    $IOSP
    Major Chemicals
    Industrials

    Parrette Leslie J bought $24,867 worth of shares (189 units at $131.57), increasing direct ownership by 4% to 4,591 units (SEC Form 4)

    4 - INNOSPEC INC. (0001054905) (Issuer)

    5/20/24 6:07:17 PM ET
    $IOSP
    Major Chemicals
    Industrials

    $IOSP
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Innospec upgraded by Seaport Research Partners with a new price target

    Seaport Research Partners upgraded Innospec from Neutral to Buy and set a new price target of $115.00

    4/21/25 8:30:53 AM ET
    $IOSP
    Major Chemicals
    Industrials

    Seaport Research Partners initiated coverage on Innospec

    Seaport Research Partners initiated coverage of Innospec with a rating of Neutral

    3/30/22 7:37:48 AM ET
    $IOSP
    Major Chemicals
    Industrials

    $IOSP
    Financials

    Live finance-specific insights

    View All

    Innospec Reports First Quarter 2026 Financial Results

    Continued strength in Fuel Specialties offset negative US winter storm impacts in other businesses Increasing confidence for sequential operating income and margin growth in Performance Chemicals and Oilfield Services Dividend increased by 10 percent; $6.2 million in share repurchases made in the quarter New $75 million buyback authorization GAAP EPS of $1.22 and adjusted non-GAAP EPS of $1.05 ENGLEWOOD, Colo., May 07, 2026 (GLOBE NEWSWIRE) -- Innospec Inc. (NASDAQ:IOSP) today announced its financial results for the first quarter ended March 31, 2026.   The Company declared its semi-annual dividend of 92 cents per common share for the first half of this year, representing an increase

    5/7/26 4:45:00 PM ET
    $IOSP
    Major Chemicals
    Industrials

    Innospec Schedules First Quarter 2026 Earnings Release and Conference Call

    ENGLEWOOD, Colo., April 07, 2026 (GLOBE NEWSWIRE) -- Innospec Inc. (NASDAQ:IOSP) today announced that it will release first quarter 2026 earnings results on Thursday, May 7, 2026 after market close. Following the release of its results, Patrick S. Williams, President and Chief Executive Officer, and Ian Cleminson, Executive Vice President and Chief Financial Officer, will host an interactive conference call on Friday, May 8, 2026, at 9:00 a.m. ET. The public is invited to listen to the conference call by registering in advance using the below Online Registration Link.   Upon registering, each participant will receive an email confirmation with dial-in numbers and a unique Personal PIN whi

    4/7/26 4:45:00 PM ET
    $IOSP
    Major Chemicals
    Industrials

    Innospec Reports Fourth Quarter and Full Year 2025 Financial Results

    Continued strength in Fuel Specialties with 7 percent operating income growth and improved margins Sequentially improving results in Performance Chemicals and Oilfield Services Excellent quarterly cash flow of $61.4 million generated from operations; Net cash improves to $292.5 million GAAP EPS $1.91 and adjusted non-GAAP EPS $1.50 ENGLEWOOD, Colo., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Innospec Inc. (NASDAQ:IOSP) today announced its financial results for the fourth quarter and full year ended December 31, 2025. Total revenues for the fourth quarter were $455.6 million, a decrease of 2 percent from $466.8 million in the corresponding period last year. Net income for the quarter was $47.4

    2/17/26 4:45:00 PM ET
    $IOSP
    Major Chemicals
    Industrials

    $IOSP
    Leadership Updates

    Live Leadership Updates

    View All

    Innospec Appoints Leslie J. Parrette as Non-Employee Director

    ENGLEWOOD, Colo., Dec. 06, 2021 (GLOBE NEWSWIRE) -- Innospec Inc. (NASDAQ:IOSP) today announced that it has appointed Mr. Leslie J. Parrette as a non-employee director, effective January 1, 2022. Mr. Parrette has 14 years experience in private practice as a corporate and transaction lawyer. He subsequently spent 20 years as General Counsel for public companies in domestic and international markets. Most recently, he served as Senior Vice President, General Counsel, Compliance Officer and Corporate Secretary of Novelis Inc., a leading producer of flat-rolled aluminum products and the world's largest recycler of aluminum. He is Founder and President of One Page Thinking, a data visualizatio

    12/6/21 4:45:00 PM ET
    $IOSP
    Major Chemicals
    Industrials

    $IOSP
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Innospec Inc. (Amendment)

    SC 13G/A - INNOSPEC INC. (0001054905) (Subject)

    2/13/24 5:06:27 PM ET
    $IOSP
    Major Chemicals
    Industrials

    SEC Form SC 13G/A filed by Innospec Inc. (Amendment)

    SC 13G/A - INNOSPEC INC. (0001054905) (Subject)

    2/9/24 2:18:58 PM ET
    $IOSP
    Major Chemicals
    Industrials

    SEC Form SC 13G/A filed by Innospec Inc. (Amendment)

    SC 13G/A - INNOSPEC INC. (0001054905) (Subject)

    1/12/24 8:24:55 AM ET
    $IOSP
    Major Chemicals
    Industrials